RDInvesting Provides Investors with Free In-Depth Equity Reports on CDXS, CLSN, MYGN and ZTS


Follow this company

Companies Mentioned

NASDAQ:CDXS / NASDAQ:CLSN / NASDAQ:MYGN / NYSE:ZTS
06/17/2013 [ACCESSWIRE]

U.S. markets losses continued Friday due to disappointing economic readings and as investors awaited the upcoming central bank's policy-committee meeting. The Standard & Poor's 500 index and the Dow Jones Industrial Average posted losses of 1.01 percent and 1.17 percent last week. On Friday, the International Monetary Fund kept its 2013 growth outlook at 1.9 percent, but lowered its 2014 growth outlook 0.3 percent to 2.7 percent. The markets recent slide is largely due to concerns that the Federal Reserve may curb its $85 billion-a-month bond-buying program. Here is how some of the top movers reacted Friday:

Codexis, Inc. (NASDAQ: CDXS) shares hit a high of $2.89 Friday before settling to close at $2.72, an increase of 25.35 percent. The stock traded in between $2.16 and$2.89 on volume of 1.79 million shares traded. On Friday, the company announced “the successful scale-up in the production of CodeXol detergent alcohols using cellulosic sugars.”

Find out more about Codexis including full access to the free equity report at:    
www.RDInvesting.com/CDXS

Celsion Corporation (NASDAQ:CLSN) shares hit a low of $1.28 Friday before settling to close at $1.45, a decrease of 13.33 percent. The stock traded in between $1.28 and $1.45 on volume of 3.98 million shares traded. On Friday, the company issued a statement regarding a misleading blog entry. Shares of Celsion have fallen approximately 84.0 percent year-to-date.

Find out more about Celsion including full access to the free equity report at:    
www.RDInvesting.com/CLSN

Myriad Genetics, Inc. (NASDAQ:MYGN) shares hit a low of $26.17 Friday before settling to close at $27.59, an increase of 13.81 percent. The stock traded in between $26.17 and $31.19 on volume of 22.7 million shares traded. On Thursday, the U.S. Supreme Court ruled that human DNA/genes cannot be patented.

Find out more about Myriad Genetics including full access to the free equity report at:    
www.RDInvesting.com/MYGN

Zoetis Inc. (NYSE:ZTS) shares declined 1.19 percent Friday to close at $30.80. The stock traded in the range of $30.61 and $31.26, on volume of 10.67 million shares traded. On Friday, S&P Dow Jones Indices LLC announced Zoetis will replace First Horizon National Corp. on the S&P 500.

Find out more about Zoetis including full access to the free equity report at:    
www.RDInvesting.com/ZTS

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:                                                                                                                                                                   
Research Driven Investing                                                                                                               
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *